Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet

Journal of Medical Economics

Volumn 16, Issue 9, 2013, Pages 1154-1162

  Belozeroff, Vasily ^a   Lee, Andrew ^a   Tseng, Spring ^a   Chiroli, Silvia ^a   Campbell, Jonathan D ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Biochemical; Cinacalcet; Costs; ESRD; OPTIMA; PTH; Response; Secondary HPT

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM DERIVATIVE; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SEVELAMER;

ARTICLE; CALCIUM BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE;

ADULT; ALGORITHMS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN D;

EID: 84882962507     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.826665     Document Type: Article

References (39)

1. Services CfMM. 42 CFR Parts 410, 413, and 414.Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule: Centers for Medicare & Medicaid Services; Federal Register. August 12, 2010
2. Watnick S, Weiner DE, Shaffer R, et al. Comparing mandated health care reforms: The Affordable Care Act, Accountable Care Organizations, and the Medicare ESRD Program. Clin J Am Soc Nephrol 2012;7:1535-43
3. Fishbane S, Miller I, Wagner JD, et al. Changes to the end-stage renal disease quality incentive program. Kidney Int 2012;81:1167-71
4. Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:2311-8 (Pubitemid 351957604)
5. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010;26:1948-55
6. Frazao JM, Messa P, Mellotte GJ, et al. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol 2011;76:233-43
7. Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24 (Pubitemid 34274098)
8. Kilpatrick R, Gill K, Block GA. Exploring the relationship between temporal trends in PTH, P and Ca in HD patients. Am Soc Nephrol 2010. Abstract and Poster
9. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011;26:1368-76
10. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71 (Pubitemid 40139871)
11. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011;26:1938-47
12. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(3 Suppl):130-5 (Pubitemid 26278603)
13. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396-9 (Pubitemid 30429887)
14. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70:1358-66 (Pubitemid 44435190)
15. Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60 (Pubitemid 47067994)
16. Shi N, Foley K, Lenhart G, et al. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009;45:1084-90
17. Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200-5
18. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295-304 (Pubitemid 41623389)
19. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93 (Pubitemid 41716485)
20. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease J Am Coll Cardiol 2002;39:695-701 (Pubitemid 34158168)
21. Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9 (Pubitemid 47122164)
22. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm Jun 2007;13:397-411 (Pubitemid 47162414)
23. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25 (Pubitemid 38477776)
24. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52 (Pubitemid 34754068)
25. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
26. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
27. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;4:CD008175
28. Kilpatrick RD, Danese MD, Belozeroff V, et al. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a casecrossover study. Pharmacoepidemiol Drug Saf 2011;20:914-21
29. Feldman RL, Desmarais MP, Muller JS. Orals in the bundle: a policy framework. Clin J Am Soc Nephrol 2013;8:1043-7
30. Drummond M. Methods for the economic evaluation of health care programmes. 3rd edn. Great Claredon St, Oxford: Oxford University Press, 2005
31. Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
32. Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108-16
33. Amgen Inc. Thousand Oaks, Ca. Sensipar(R) Package Insert
34. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health: J Int Soc Pharmacoecon Outcomes Res 2009;12:409-18
35. Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15:509-20
36. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:801-13 (Pubitemid 46802934)
37. Plosker GL. Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease. Pharmacoeconomics 2011;29:807-21
38. Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;29:1041-54
39. Moe SM, Drueke TB. The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence. Kidney Int 2011;79:478; author reply 478-9